Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Curza Inc secured a $1,000,000 NIH SBIR/STTR award: New oral antibiotics focused on treating MDR Gram-negative infections
Amount Raised
$1 Million
Round Type
Grant
Salt Lake CityHealthcareInvestors
Description
Project Summary Cūrza is developing a new class of broad-spectrum antibiotics, focused on multidrug-resistant (MDR) Gram- negative pathogens. The CZ-02 program is directed towards inhibitors that bind to a unique site on the bacterial ribosome that is not targeted by approved antibiotics and have not encountered cross-resistance to other antibiotics used clinically. Inspired by a natural product, analogs have been developed that selectively inhibit bacterial protein synthesis, with little effect
Related People
Funding Insights
Based on industry dataWatching Curza? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your plan